If you find this podcast useful please give it a rating and review on iTunes by clicking here

Jeremy Skillington, CEO of Poolbeg Pharma discusses the positive initial data analysis in POLB 001 LPS Challenge Trial and says a full data read-out is expected in Q2 2023 following a final quality check of the unblinded data.
Highlights
- POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo
- A clear dose-response relationship was demonstrated
- Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported
- Full data read-out expected in Q2 2023 following a final quality check of the unblinded data

